2-氟-6-甲基吡啶-3-硼酸 | 906744-85-2

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-氟-6-甲基吡啶-3-硼酸
• 中文别名: (2-氟-6-甲基吡啶3-基)硼酸
• 英文名称: (2-fluoro-6-methylpyridin-3-yl)boronic acid
• 英文别名: 2-Fluoro-6-methylpyridine-3-boronic acid
• CAS: 906744-85-2
• 化学式: C₆H₇BFNO₂
• mdl: MFCD03411560
• 分子量: 154.936
• InChiKey: QIIKPLRESDHKTN-UHFFFAOYSA-N

物化性质

• 沸点：
  308.4±52.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  53.4
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P233,P260,P261,P264,P270,P271,P280,P301+P312,P302+P352,P304,P304+P340,P305+P351+P338,P312,P321,P330,P332+P313,P337+P313,P340,P362,P403,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Fluoro-6-methylpyridine-3-boronic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Fluoro-6-methylpyridine-3-boronic acid
CAS number: 906744-85-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H7BFNO2
Molecular weight: 154.9

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氟-6-甲基吡啶-3-硼酸 、 4-氨基-8-溴-N-丙基氮杂嗪-3-胺 以38%的产率得到4-Amino-8-(2-fluoro-6-methylpyridin-3-yl)-cinnoline-3-carboxylic acid propylamide
  参考文献：
  名称：

  Compounds and Uses Thereof - 849

  摘要：

  本发明涉及使用具有以下结构式I的化合物及其药用可接受的盐、互变异构体或体内可水解的前体，在治疗精神分裂症方面的组合物。

  公开号：

  US20080318925A1

文献信息

• Microwave-Assisted Flexible Synthesis of 7-Azaindoles
  作者：Hartmut Schirok

  DOI：10.1021/jo060512h

  日期：2006.7.1

  7-Azaindoles are versatile building blocks, especially in medicinal chemistry, where they serve as bioisosteres of indoles or purines. Herein, we are presenting a robust and flexible synthesis of 1,3- and 1,3,6-substituted 7-azaindoles starting from nicotinic acid derivatives or 2,6-dichloropyridine, respectively. Microwave heating dramatically accelerates the penultimate reaction step, an epoxide

  7-氮杂吲哚是多用途的构建基块，尤其是在药物化学中，它们可作为吲哚或嘌呤的生物等排体。在本文中，我们提出了分别从烟酸衍生物或2,6-二氯吡啶开始的1、3和1,3,6-取代的7-氮杂吲哚的稳健而灵活的合成。微波加热极大地加速了倒数第二个反应步骤，即环氧化物-开环-脱水过程。检查反应的官能团相容性以及产物在进一步官能化中的应用。
• 酞嗪酮类化合物、其制备方法、药物组合物及 用途
  申请人：中国科学院上海药物研究所

  公开号：CN109134429B

  公开（公告）日：2021-06-01

  酞嗪酮类化合物、其制备方法、药物组合物及用途，所述酞嗪酮类化合物结构如式I所示，所述式I化合物靶向作用于病毒核壳体，可通过对病毒核壳体的干扰抑制病毒的复制，具有高效的抑制乙型肝炎病毒DNA复制的活性，且具有较好的肝脏靶向性，能在肝脏稳定存在并富集，是一类新型的、有效的抗乙型肝炎病毒抑制剂。
• Discovery of Phthalazinone Derivatives as Novel Hepatitis B Virus Capsid Inhibitors
  作者：Wuhong Chen、Feifei Liu、Qiliang Zhao、Xinna Ma、Dong Lu、Heng Li、Yanping Zeng、Xiankun Tong、Limin Zeng、Jia Liu、Li Yang、Jianping Zuo、Youhong Hu

  DOI：10.1021/acs.jmedchem.0c00346

  日期：2020.8.13

  On the basis of a lead compound 4r, we further investigated this target to identify novel active compounds with appropriate anti-HBV potencies and improved pharmacokinetic (PK) properties. Structure–activity relationship studies based on metabolic pathways of 4r led to the identification of a phthalazinone derivative 19f with appropriate anti-HBV potencies (IC50 = 0.014 ± 0.004 μM in vitro), which demonstrated

  HBV衣壳组装已被视为针对HBV的新抗病毒治疗的诱人靶标。在前导化合物4r的基础上，我们进一步研究了该目标，以鉴定具有适当的抗HBV效能和改善的药代动力学（PK）特性的新型活性化合物。基于4r代谢途径的结构-活性关系研究导致鉴定出具有适当抗HBV效能（体外IC 50 = 0.014±0.004μM ）的酞嗪酮衍生物19f，表明口服生物利用度高和肝暴露。在AAV-HBV /小鼠模型中，管理19f 导致在以150 mg / kg的剂量每天给药两次的4周治疗期间，HBV DNA病毒载量减少了2.67 log。
• Design, Synthesis, and Biological Evaluation of 4-Quinoline Carboxylic Acids as Inhibitors of Dihydroorotate Dehydrogenase
  作者：Joseph T. Madak、Christine R. Cuthbertson、Yoshinari Miyata、Shuzo Tamura、Elyse M. Petrunak、Jeanne A. Stuckey、Yanyan Han、Miao He、Duxin Sun、Hollis D. Showalter、Nouri Neamati

  DOI：10.1021/acs.jmedchem.7b01862

  日期：2018.6.28

  We pursued a structure-guided approach toward the development of improved dihydroorotate dehydrogenase (DHODH) inhibitors with the goal of forming new interactions between DHODH and the brequinar class of inhibitors. Two potential residues, T63 and Y356, suitable for novel H-bonding interactions, were identified in the brequinar-binding pocket. Analogues were designed to maintain the essential pharmacophore

  我们追求一种结构导向的方法来开发改进的二氢乳清酸脱氢酶 (DHODH) 抑制剂，目标是在 DHODH 和 brequinar 类抑制剂之间形成新的相互作用。在 brequinar 结合口袋中鉴定了两个潜在的残基，T63 和 Y356，适用于新的 H 键相互作用。类似物旨在维持基本的药效团并通过战略性定位的氢键接受基团形成新的静电相互作用。这一努力导致发现了有效的基于喹啉的类似物41 (DHODH IC 50 = 9.71 ± 1.4 nM) 和43 (DHODH IC 50 = 26.2 ± 1.8 nM)。43之间的共晶结构DHODH 描述了一种新的水介导的与 T63 的氢键相互作用。额外的优化导致 1,7-萘啶46 (DHODH IC 50 = 28.3 ± 3.3 nM) 与 Y356 形成新的氢键。重要的是，化合物41具有显着的口服生物利用度 ( F = 56%) 和消除t 1/2
• [EN] PYRROLOPYRIDAZINE COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRROLOPYRIDAZINE UTILISÉS COMME INHIBITEURS DE KINASE
  申请人：GOSSAMER BIOSERVICES INC

  公开号：WO2022109492A1

  公开（公告）日：2022-05-27

  Described herein are inhibitors of JAK kinases, pharmaceutical compositions comprising them, processes for preparing them and uses of such inhibitors to treat or prevent diseases, disorders and conditions associated with kinase function.

  本文描述了JAK激酶抑制剂，包括它们的制药组合物、制备它们的过程以及使用这些抑制剂来治疗或预防与激酶功能相关的疾病、紊乱和病况。